Abstract: The present invention relates to Human Immunodeficiency Virus (HIV) prevention and treatment. In particular, the invention relates to a pharmaceutical composition comprising: cabotegravir; a wetting agent; a stabilizer; and a tonicity adjuster; wherein cabotegravir is present in the form of particles having a mass median diameter (X50) of between (and including) 2.5 ?m and 10 ?m.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib (Formula I) as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: An example system includes a service proxy controller and a number of service proxy workers. The service proxy controller is configured for providing routing policies for a telecommunications network core. The telecommunications network core includes network functions communicating using a service-based architecture. Each service proxy worker is configured for routing telecommunications network core messages between a respective subset of the network functions by consuming the routing policies from the service proxy controller and enforcing the routing policies from the service proxy controller. Each service proxy worker is configured for providing network status reports to the service proxy controller based on the telecommunications network core messages.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: An example system includes a service proxy controller and a number of service proxy workers. The service proxy controller is configured for providing routing policies for a telecommunications network core. The telecommunications network core includes network functions communicating using a service-based architecture. Each service proxy worker is configured for routing telecommunications network core messages between a respective subset of the network functions by consuming the routing policies from the service proxy controller and enforcing the routing policies from the service proxy controller. Each service proxy worker is configured for providing network status reports to the service proxy controller based on the telecommunications network core messages.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: A policy and charging rules function (PCRF), generates a Diameter audit message concerning an application level Diameter session for which local resources are maintained by the PCRF. The PCRF includes, in the audit message, a fake parameter value. The PCRF sends the audit message with the fake parameter value to the OCS or the AF over an Sy or Rx interface. The PCRF receives a response to the audit message from the OCS or AF. The PCRF determines, based on the response, whether the application level session comprises and orphan session. The PCRF, in response to determining that the application level Diameter session comprises an orphan session frees the local resources maintained by the PCRF for the orphan session.

Abstract: The subject matter described herein includes systems, methods, and computer readable media for utilizing quota usage policy control in a Diameter-based communication network. An exemplary method includes, at a policy server, sending a request for quota usage information associated with a subscriber to an online charging system (OCS) node. The method further includes receiving the quota usage information from the OCS node, generating at least one policy and charging control (PCC) rule for modifying a quality of service (QoS) policy attribute associated with the subscriber based on the quota usage information, and communicating the at least one PCC rule to a Diameter network element.

Abstract: A policy and charging rules function (PCRF), generates a Diameter audit message concerning an application level Diameter session for which local resources are maintained by the PCRF. The PCRF includes, in the audit message, a fake parameter value. The PCRF sends the audit message with the fake parameter value to the OCS or the AF over an Sy or Rx interface. The PCRF receives a response to the audit message from the OCS or AF. The PCRF determines, based on the response, whether the application level session comprises and orphan session. The PCRF, in response to determining that the application level Diameter session comprises an orphan session frees the local resources maintained by the PCRF for the orphan session.